Autolus Therapeutics to Present Preclinical Data on AUT06NG at the SITC Annual Meeting
05 nov. 2019 09h35 HE
|
Autolus Therapeutics plc
LONDON, Nov. 05, 2019 (GLOBE NEWSWIRE) -- Autolus Therapeutics plc (Nasdaq: AUTL), a clinical-stage biopharmaceutical company developing next-generation programmed T cell therapies for the treatment...
Autolus Therapeutics to Report Third Quarter 2019 Financial Results and Host Conference Call on November 7
31 oct. 2019 06h30 HE
|
Autolus Therapeutics plc
LONDON, Oct. 31, 2019 (GLOBE NEWSWIRE) -- Autolus Therapeutics plc (Nasdaq: AUTL), a clinical-stage biopharmaceutical company developing next-generation programmed T cell therapies, today announced...
Autolus Announces Changes to Executive Leadership Team
08 oct. 2019 08h00 HE
|
Autolus Therapeutics plc
LONDON, Oct. 08, 2019 (GLOBE NEWSWIRE) -- Autolus Therapeutics plc (Nasdaq: AUTL), a clinical-stage biopharmaceutical company developing next-generation programmed T cell therapies, today announced...
Autolus Therapeutics to Participate in Upcoming Investor Conferences in June
28 mai 2019 16h55 HE
|
Autolus Therapeutics plc
LONDON, May 28, 2019 (GLOBE NEWSWIRE) -- Autolus Therapeutics plc (Nasdaq: AUTL), a clinical-stage biopharmaceutical company developing next-generation programmed T cell therapies, today announced...
Autolus Therapeutics Reports First Quarter 2019 Financial Results and Operational Progress
14 mai 2019 06h30 HE
|
Autolus Therapeutics plc
LONDON, May 14, 2019 (GLOBE NEWSWIRE) -- Autolus Therapeutics plc (Nasdaq: AUTL), a clinical-stage biopharmaceutical company developing next-generation programmed T cell therapies, today announced...
Autolus Therapeutics Receives FDA Orphan Drug Designation for AUTO3 for Treatment of Acute Lymphoblastic Leukemia
23 avr. 2019 07h49 HE
|
Autolus Therapeutics plc
LONDON, April 23, 2019 (GLOBE NEWSWIRE) -- Autolus Therapeutics plc (Nasdaq: AUTL), a clinical-stage biopharmaceutical company developing next-generation programmed T cell therapies for the...
ERYTECH partecipa alle prossime conferenze degli investitori
13 sept. 2018 17h30 HE
|
Erytech Pharma S.A.
LIONE, Francia, Sept. 13, 2018 (GLOBE NEWSWIRE) -- ERYTECH Pharma (Euronext Paris: ERYP - Nasdaq: ERYP), una società biofarmaceutica di fase clinica che sviluppa terapie innovative incapsulando...
ERYTECH nimmt an kommenden Investorenkonferenzen teil
13 sept. 2018 17h30 HE
|
Erytech Pharma S.A.
LYON, Frankreich, Sept. 13, 2018 (GLOBE NEWSWIRE) -- ERYTECH Pharma (Euronext Paris: ERYP - Nasdaq: ERYP), ein in der klinischen Entwicklungsphase tätiges Biopharma-Unternehmen, das innovative...
ERYTECH participera à plusieurs conférences d'investisseurs
13 sept. 2018 01h30 HE
|
Erytech Pharma S.A.
LYON, France, 13 sept. 2018 (GLOBE NEWSWIRE) -- ERYTECH Pharma (Euronext : ERYP – Nasdaq : ERYP), société biopharmaceutique de stade clinique qui développe des thérapies innovantes en encapsulant...
ERYTECH to Attend Upcoming Investor Conferences
13 sept. 2018 01h30 HE
|
Erytech Pharma S.A.
LYON, France, Sept. 13, 2018 (GLOBE NEWSWIRE) -- ERYTECH Pharma (Euronext Paris: ERYP - Nasdaq: ERYP), a clinical-stage biopharmaceutical company developing innovative therapies by encapsulating...